Treatment de-intensification strategies for head and neck cancer

Eur J Cancer. 2016 Nov:68:125-133. doi: 10.1016/j.ejca.2016.09.006. Epub 2016 Oct 15.

Abstract

Increasingly, squamous cell carcinoma of the oropharynx (OPSCC) is attributable to transformation resulting from high-risk human papillomavirus (HPV) infection. Such cancers are significantly more responsive to treatment than traditional tobacco- and alcohol-associated squamous cell cancers of the head and neck. Conventional management with definitive chemoradiation, surgery and adjuvant radiation, or radiation given with altered fractionation schemes, while effective, incurs long-term morbidity that escalates with treatment intensity and significantly impairs quality of life. Recent trials have suggested that less intensive treatment regimens may achieve similar efficacy with decreased toxicity. In this article, we review the primary strategies used for de-escalation of treatment, which include the reduction of radiation dose, substitution and/or elimination of concurrent radiosensitising chemotherapy, and the use of minimally invasive surgery. We discuss the rationale behind these approaches and the preliminary data demonstrating the success of de-escalation, as well as potential considerations raised by treatment de-intensification in HPV-associated OPSCC.

Keywords: Carcinoma; Chemotherapy; Clinical trial; Head and neck; Human papillomavirus; Oropharyngeal neoplasms; Oropharynx; Radiotherapy; Squamous cell; Surgery.

Publication types

  • Review

MeSH terms

  • Carcinoma, Squamous Cell / therapy*
  • Carcinoma, Squamous Cell / virology
  • Chemoradiotherapy
  • Combined Modality Therapy
  • Head and Neck Neoplasms / therapy*
  • Head and Neck Neoplasms / virology
  • Humans
  • Minimally Invasive Surgical Procedures
  • Oropharyngeal Neoplasms / therapy*
  • Oropharyngeal Neoplasms / virology
  • Otorhinolaryngologic Surgical Procedures
  • Papillomavirus Infections / therapy*
  • Papillomavirus Infections / virology
  • Radiotherapy Dosage
  • Radiotherapy, Adjuvant
  • Squamous Cell Carcinoma of Head and Neck